The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 15, 2022
Filed:
Feb. 09, 2016
Applicant:
Synta Pharmaceuticals Corp., Lexington, MA (US);
Inventors:
David A. Proia, Newton, MA (US);
Patricia E. Rao, Acton, MA (US);
Assignee:
Synta Pharmaceuticals Corp., Lexington, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 31/4196 (2006.01); A61K 39/395 (2006.01); A61K 31/6615 (2006.01); C07K 16/28 (2006.01); A61K 31/675 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4196 (2013.01); A61K 31/6615 (2013.01); A61K 31/675 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/3046 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01);
Abstract
A pharmaceutical composition comprising a PD-1 inhibitor and a Hsp90 inhibitor, or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4] triazole or 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate. Also provided is a method for treating cancer in a subject in need thereof, using the pharmaceutical composition described herein.